 |  |
Search IPO GMP:
Molbio Diagnostics IPO GMP, Latest Grey Market Premium Today
Molbio Diagnostics is a Mainboard IPO, the company will raise up to 939.85 crore rupees for 1,16,46,246 shares. The IPO comprises a fresh issue of 24,80,246 shares (aggregating up to 200.15 crore rupees), and an offer for sale (OFS) of 91,66,000 shares (aggregating up to 739.70 crore rupees).
Molbio Diagnostics IPO GMP (Grey Market Premium) Today
Visit us daily to get the latest update on Molbio Diagnostics IPO GMP. IPO GMP started, and here you can get the latest update of Molbio Diagnostics IPO GMP.
Molbio Diagnostics IPO GMP today or grey market premium, and the Latest GMP Data is available here.
- Price Band of Molbio Diagnostics IPO is ₹768 to ₹807 per share.
- Current GMP (Grey Market Premium) for Molbio Diagnostics IPO is:
- It is a premium for the Molbio Diagnostics IPO cut-off price .
- As per Molbio Diagnostics IPO Taday’s GMP Data, the estimated listing price per shares can be:
- Estimated listing price calculated as IPO cutoff price or allotment price: + IPO current GMP: .
Molbio Diagnostics IPO GMP | ||
| Date | GMP (₹) | Listing Price (₹-Estimated) |
| Today | 148 | |
| 12 August 2026 | 148 | |
| 11 August 2026 | 116 | |
| 10 August 2026 | 120 | |
| 9 August 2026 | 120 | |
| 8 August 2026 | 118 | |
| 7 August 2026 | 180 | |
| 6 August 2026 | 180 | |
| 5 August 2026 | 170 | |
Molbio Diagnostics opened for subscription on 10 August 2026 (Monday) and closed on 12 August 2026 (Wednesday). Basis of allotment was decided on 13 August 2026 (Thursday), initiation of refund began on 14 August 2026 (Friday) and IPO was listed on 17 August 2026 (Monday) at NSE, BSE. IIFL Capital Services Ltd, Jefferies India Pvt Ltd, Kotak Mahindra Capital Co Ltd and Motilal Oswal Investment Advisors Ltd is the book running lead manager and Kfin Technologies Ltd is the registrar of the IPO.
Total shares offered by Molbio Diagnostics is 1,16,46,246 shares (aggregating up to 939.85 crore rupees). Out of which Not less than 35% of the offer is reserved for retail, Not less than 15% of the offer is reserved for HNI (NII), Not more than 50% of the offer is reserved for QIB.
Molbio Diagnostics IPO Price Band and Market Lot
Molbio Diagnostics has set a price band of ₹768 to ₹807 per share and lot size is of 18 shares. Retail investors could bid for a minimum of 1 lots (18 shares), requiring minimum investment of ₹14,526, and maximum upto 13 lots (234 shares), requiring maximum investment of ₹1,88,838. Small HNI investors could bid for a minimum of 14 lots (252 shares), requiring an investment of ₹2,03,364, small hni (shni) investors could bid for a maximum of 68 lots (1,224 shares), requiring an investment of ₹9,87,768 and big hni (bHNI) investors could bid for a minimum of 69 Lots (1,242 shares), requiring an investment of ₹10,02,294. Calculated at the cut-off price ₹807 per share per share (the upper end of the price band).
About Molbio Diagnostics
Incoprated in 2000, headquartered in Verna, Goa, Molbio Diagnostics is a medical technology company that develops portable molecular diagnostic solutions for point of care testing. The company is best known for its proprietary Truenat platform, a portable, battery operated real time PCR system designed to deliver rapid and accurate molecular test results outside conventional laboratories.Molbio Diagnostics IPO GMP FAQs
The latest Grey Market Premium (GMP) of Molbio Diagnostics IPO is .
It is a premium to the IPO cut-off price of Molbio Diagnostics. GMP gives a rough estimate of the premium at which the stock might list. It’s not guaranteed but often aligns with market sentiment.
As per latest GMP data, the expected return for Molbio Diagnostics IPO can be .
Expected listing listing price for Molbio Diagnostics share can be .
According to latest GMP data pattern expected listing price and profit per share for Molbio Diagnostics IPO can be . Expected listing price is calculated by adding the GMP to the IPO issue price. Estimated listing price = IPO issue price + current GMP. This value changes as the GMP fluctuates.
GMP is an unofficial indicator and can be manipulated. It should never be the sole reason to apply. Always consider Molbio Diagnostics fundamentals and your risk tolerance. Subscription demand, financial performance, market sentiment, peer valuation, and overall liquidity can impact the GMP trend.
Grey Market Premium (GMP) refers to the unofficial over-the-counter market where IPO shares or applications are traded before listing on stock exchanges. GMP data is based on market speculation, demand, subscriptions, and market sentiment, and may change rapidly without notice. Since the grey market is unregulated, GMP figures may be volatile, inaccurate, or subject to manipulation.
GMP should not be considered the sole basis for making investment decisions. The information provided by MarketBandhu is for informational purposes only (gathered from various sources) and does not constitute financial, investment, or trading advice. MarketBandhu does not recommend buying, selling, or subscribing to any IPO based solely on GMP data.